Page last updated: 2024-12-04

oxamic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxamic acid is a white crystalline solid with the formula H2NC(=O)COOH. It is the simplest oxamic acid derivative. Oxamic acid can be synthesized by reacting oxalic acid with urea. The compound is often used as a reagent in organic chemistry, as it is a good source of the oxamate anion. Oxamic acid has a wide range of biological activities, including anti-inflammatory, antioxidant, and antitumor activities. It has also been studied for its potential use in treating diabetes. Oxamic acid is an important compound in the field of biochemistry, as it is involved in the biosynthesis of amino acids. It is also studied for its role in the regulation of metabolic pathways.'

Oxamic Acid: Amino-substituted glyoxylic acid derivative. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

oxamic acid : A dicarboxylic acid monoamide resulting from the formal condensation of one of the carboxy groups of oxalic acid with ammonia. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID974
CHEMBL ID15976
CHEBI ID18058
MeSH IDM0015633

Synonyms (66)

Synonym
nsc-53102
nsc-49416
amino(oxo)acetic acid
CHEBI:18058 ,
formic acid, (aminocarbonyl)-
nsc47001
oxalamic acid
oxamate, (aminocarbonyl)-
oxalic acid monoamide
formic acid, carbamoyl-
nsc-47001
acetic acid, aminooxo-
glycine, 2-oxo-
glyoxylic acid, amino-
oxamidic acid
oxamate (insect repellant)
oxamate (repellent)
CMAP_000019
LOPAC0_000913
oxm ,
oxamic acid
C01444
471-47-6
oxalic monoamide
DB03940
KBIO2_004884
KBIOSS_002318
KBIO2_007452
KBIO2_002316
KBIOGR_002316
KBIO3_002796
oxamate, 3
carbamoylformic acid
bdbm23222
oxamic acid, >=98%
0DF4C36B-13CB-4AB3-8E3A-62D7C14449F1
aminooxoacetic acid
CHEMBL15976
O0084
66257-53-2
AKOS009156490
einecs 207-443-0
ai3-52243
acetic acid, 2-amino-2-oxo-
unii-qu60n5oplg
nsc 47001
qu60n5oplg ,
FT-0632178
hgy ,
oxamic acid [mi]
SOWBFZRMHSNYGE-UHFFFAOYSA-N
2-amino-2-oxoacetic acid
DTXSID6060052
oxamicacid
c2h3no3
mfcd00008006
AS-58193
in-18474 oxamic acid
Q27094801
SDCCGSBI-0050888.P002
A872204
SY012751
CS-W013748
EN300-113507
carboxy amide
Z424779074

Research Excerpts

Actions

ExcerptReferenceRelevance
"Oxamic acid did not inhibit Pf MDH, while gossypol, which interacts at the nucleotide binding site of oxidoreductases and shows antimalarial activity, inhibited Pf MDH also."( An alpha-proteobacterial type malate dehydrogenase may complement LDH function in Plasmodium falciparum. Cloning and biochemical characterization of the enzyme.
Avery, MA; Desai, PV; Khan, SI; Pradhan, A; Tekwani, BL; Tripathi, AK; Walker, LA, 2004
)
1.04

Toxicity

ExcerptReferenceRelevance
" Both drugs were safe for topical ophthalmic use when used four times daily for up to 28 days."( Efficacy and safety of lodoxamide 0.1% vs cromolyn sodium 4% in patients with vernal keratoconjunctivitis.
Caldwell, DR; Drake, MM; Hartwich-Young, R; Meyer, SM; Verin, P, 1992
)
0.28
" No side effect related to the use of the drug has been noted."( [Evaluation of efficacy and safety of sterile solution of lodoxamide in patients with ocular allergy].
Nicoară, S, 2001
)
0.31
" Cisplatin was significantly more toxic in confluent monolayers of LLC-PK(1) cells that overexpressed mitAspAT than in control cells containing vector alone."( Cisplatin-induced toxicity is associated with platinum deposition in mouse kidney mitochondria in vivo and with selective inactivation of the alpha-ketoglutarate dehydrogenase complex in LLC-PK1 cells.
Bubber, P; Cooper, AJ; Gibson, GE; Hanigan, MH; Krasnikov, BF; Pinto, JT; Xu, H; Zhang, L, 2006
)
0.33
"Topical lodoxamide eye drops, when used for treatment of VKC, are effective with fewer adverse effects."( Safety and efficacy of lodoxamide in vernal keratoconjunctivitis.
Alam, R; Das, D; Gul, A; Khan, M, 2011
)
0.37
" This medication has proved to be safe and well tolerated."( Efficacy and safety of 0.1% lodoxamide for the long-term treatment of superior limbic keratoconjunctivitis.
Gonzalez-Gonzalez, JM; Macias-Rodriguez, Y; Rodriguez-Garcia, A, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
" The experiments suggesting a relationship between the activity and the bioavailability of the ester 19 are also described."( Troponoids. 3. Synthesis and antiallergy activity of N-troponyloxamic acid esters.
Bagli, JF; Bogri, T; Lippmann, W; Martel, R; Palameta, B; Pugsley, T; Robinson, W, 1979
)
0.5
"Through structural modification of an oxalamide derived chemotype, a novel class of highly potent, orally bioavailable IDO1-specific inhibitors was identified."( Discovery of highly potent heme-displacing IDO1 inhibitors based on a spirofused bicyclic scaffold.
Albers, M; Anderhub, S; Czekańska, M; Hoffmann, T; Hornberger, M; Kinzel, O; Mallinger, A; Morschhaeuser, B; Pinto, S; Sonnek, C; Steeneck, C; Wang, Y, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" The neutrophil dose-response curve for increase in XO paralleled closely the curve for neutrophil-mediated RPAEC cytotoxicity."( Xanthine oxidase activity in rat pulmonary artery endothelial cells and its alteration by activated neutrophils.
Gannon, DE; Phan, SH; Ryan, US; Varani, J; Ward, PA, 1989
)
0.28
" Attempts were made to decrease the theophylline dosage by sequentially reducing the dose each week to one-half, one-quarter, and discontinuation."( Lack of significant arrhythmogenicity from chronic theophylline and beta-2-adrenergic combination therapy in asthmatic subjects.
Kelly, HW; Menendez, R; Voyles, W, 1985
)
0.27
" Analysis of allergen dose-response curve parameters shows that pretreatment with lodoxamide offers significant protection against experimental allergen-induced bronchoconstriction."( Protective effect opf lodoxamide tromethamine on allergen inhalation challenge.
Bewtra, AK; Bui, TC; Townley, RG; Watt, GD, 1980
)
0.26
" This effect was greatest when oxamate was dosed after Dox, suggesting that oxamate inhibited repair of Dox-induced damage."( Modification of tumour glucose metabolism for therapeutic benefit.
Fennell, M; Hamilton, E; Stafford, DM, 1995
)
0.29
" Uses include screening compounds for gross metabolic effects in mammalian cell lines, determining preliminary metabolic dose-response curves for guiding further research, and designing and optimizing media for in vitro systems utilizing cell cultures."( 24-well plate spectrophotometric assay for preliminary screening of metabolic activity.
Balcarcel, RR; Yang, Y, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dicarboxylic acid monoamide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Allantoin Degradation (Anaerobic)518

Protein Targets (15)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
L-lactate dehydrogenase A chainHomo sapiens (human)Ki109.50000.05003.76508.5000AID1267459; AID1276043; AID586286; AID724997
Malate dehydrogenase, mitochondrialSus scrofa (pig)IC50 (µMol)1,369.25002.03004.26839.5400AID1798305; AID296880
L-lactate dehydrogenase B chainHomo sapiens (human)Ki94.40000.05000.77001.4000AID1276044; AID1411565
Malate dehydrogenase, cytoplasmicSus scrofa (pig)IC50 (µMol)1,369.25002.03004.76839.5400AID1798305; AID296881
5-hydroxytryptamine receptor 7Cavia porcellus (domestic guinea pig)IC50 (µMol)1,237.00002.03005.53139.9000AID296877; AID296879
Bcl-2-like protein 1Homo sapiens (human)IC50 (µMol)1,243.10000.00031.04829.5400AID1798305
L-lactate dehydrogenasePlasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)92.50002.64002.64002.6400AID296877
L-lactate dehydrogenasePlasmodium falciparum CDC/HondurasIC50 (µMol)1,243.10002.03004.56209.5400AID1798305
L-lactate dehydrogenase B chainBos taurus (cattle)IC50 (µMol)1,243.10002.03004.56209.5400AID1798305
L-lactate dehydrogenasePlasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)2,000.00002.03002.03002.0300AID296879
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (47)

Processvia Protein(s)Taxonomy
lactate metabolic processL-lactate dehydrogenase A chainHomo sapiens (human)
pyruvate metabolic processL-lactate dehydrogenase A chainHomo sapiens (human)
glycolytic processL-lactate dehydrogenase A chainHomo sapiens (human)
lactate metabolic processL-lactate dehydrogenase B chainHomo sapiens (human)
pyruvate metabolic processL-lactate dehydrogenase B chainHomo sapiens (human)
NAD metabolic processL-lactate dehydrogenase B chainHomo sapiens (human)
response to cytokineBcl-2-like protein 1Homo sapiens (human)
negative regulation of apoptotic processBcl-2-like protein 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsBcl-2-like protein 1Homo sapiens (human)
ovarian follicle developmentBcl-2-like protein 1Homo sapiens (human)
in utero embryonic developmentBcl-2-like protein 1Homo sapiens (human)
release of cytochrome c from mitochondriaBcl-2-like protein 1Homo sapiens (human)
endocytosisBcl-2-like protein 1Homo sapiens (human)
germ cell developmentBcl-2-like protein 1Homo sapiens (human)
spermatogenesisBcl-2-like protein 1Homo sapiens (human)
male gonad developmentBcl-2-like protein 1Homo sapiens (human)
apoptotic mitochondrial changesBcl-2-like protein 1Homo sapiens (human)
fertilizationBcl-2-like protein 1Homo sapiens (human)
regulation of cytokinesisBcl-2-like protein 1Homo sapiens (human)
positive regulation of mononuclear cell proliferationBcl-2-like protein 1Homo sapiens (human)
ectopic germ cell programmed cell deathBcl-2-like protein 1Homo sapiens (human)
regulation of growthBcl-2-like protein 1Homo sapiens (human)
negative regulation of apoptotic processBcl-2-like protein 1Homo sapiens (human)
negative regulation of neuron apoptotic processBcl-2-like protein 1Homo sapiens (human)
dendritic cell proliferationBcl-2-like protein 1Homo sapiens (human)
response to cycloheximideBcl-2-like protein 1Homo sapiens (human)
regulation of mitochondrial membrane permeabilityBcl-2-like protein 1Homo sapiens (human)
epithelial cell proliferationBcl-2-like protein 1Homo sapiens (human)
negative regulation of developmental processBcl-2-like protein 1Homo sapiens (human)
neuron apoptotic processBcl-2-like protein 1Homo sapiens (human)
defense response to virusBcl-2-like protein 1Homo sapiens (human)
regulation of mitochondrial membrane potentialBcl-2-like protein 1Homo sapiens (human)
cellular response to amino acid stimulusBcl-2-like protein 1Homo sapiens (human)
cellular response to alkaloidBcl-2-like protein 1Homo sapiens (human)
cellular response to gamma radiationBcl-2-like protein 1Homo sapiens (human)
apoptotic process in bone marrow cellBcl-2-like protein 1Homo sapiens (human)
negative regulation of release of cytochrome c from mitochondriaBcl-2-like protein 1Homo sapiens (human)
dendritic cell apoptotic processBcl-2-like protein 1Homo sapiens (human)
hepatocyte apoptotic processBcl-2-like protein 1Homo sapiens (human)
negative regulation of execution phase of apoptosisBcl-2-like protein 1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damageBcl-2-like protein 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayBcl-2-like protein 1Homo sapiens (human)
negative regulation of protein localization to plasma membraneBcl-2-like protein 1Homo sapiens (human)
negative regulation of reproductive processBcl-2-like protein 1Homo sapiens (human)
negative regulation of dendritic cell apoptotic processBcl-2-like protein 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandBcl-2-like protein 1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayBcl-2-like protein 1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageBcl-2-like protein 1Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandBcl-2-like protein 1Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processBcl-2-like protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
L-lactate dehydrogenase activityL-lactate dehydrogenase A chainHomo sapiens (human)
protein bindingL-lactate dehydrogenase A chainHomo sapiens (human)
identical protein bindingL-lactate dehydrogenase A chainHomo sapiens (human)
cadherin bindingL-lactate dehydrogenase A chainHomo sapiens (human)
L-lactate dehydrogenase activityL-lactate dehydrogenase B chainHomo sapiens (human)
protein bindingL-lactate dehydrogenase B chainHomo sapiens (human)
kinase bindingL-lactate dehydrogenase B chainHomo sapiens (human)
identical protein bindingL-lactate dehydrogenase B chainHomo sapiens (human)
NAD bindingL-lactate dehydrogenase B chainHomo sapiens (human)
protein bindingBcl-2-like protein 1Homo sapiens (human)
protein kinase bindingBcl-2-like protein 1Homo sapiens (human)
identical protein bindingBcl-2-like protein 1Homo sapiens (human)
BH3 domain bindingBcl-2-like protein 1Homo sapiens (human)
BH domain bindingBcl-2-like protein 1Homo sapiens (human)
L-lactate dehydrogenase activityL-lactate dehydrogenase B chainBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
nucleusL-lactate dehydrogenase A chainHomo sapiens (human)
cytosolL-lactate dehydrogenase A chainHomo sapiens (human)
membraneL-lactate dehydrogenase A chainHomo sapiens (human)
extracellular exosomeL-lactate dehydrogenase A chainHomo sapiens (human)
oxidoreductase complexL-lactate dehydrogenase A chainHomo sapiens (human)
mitochondrionL-lactate dehydrogenase A chainHomo sapiens (human)
cytoplasmL-lactate dehydrogenase B chainHomo sapiens (human)
mitochondrial inner membraneL-lactate dehydrogenase B chainHomo sapiens (human)
cytosolL-lactate dehydrogenase B chainHomo sapiens (human)
membraneL-lactate dehydrogenase B chainHomo sapiens (human)
membrane raftL-lactate dehydrogenase B chainHomo sapiens (human)
extracellular exosomeL-lactate dehydrogenase B chainHomo sapiens (human)
oxidoreductase complexL-lactate dehydrogenase B chainHomo sapiens (human)
mitochondrionL-lactate dehydrogenase B chainHomo sapiens (human)
cytoplasmBcl-2-like protein 1Homo sapiens (human)
mitochondrionBcl-2-like protein 1Homo sapiens (human)
mitochondrial outer membraneBcl-2-like protein 1Homo sapiens (human)
mitochondrial inner membraneBcl-2-like protein 1Homo sapiens (human)
mitochondrial matrixBcl-2-like protein 1Homo sapiens (human)
endoplasmic reticulumBcl-2-like protein 1Homo sapiens (human)
centrosomeBcl-2-like protein 1Homo sapiens (human)
cytosolBcl-2-like protein 1Homo sapiens (human)
synaptic vesicle membraneBcl-2-like protein 1Homo sapiens (human)
nuclear membraneBcl-2-like protein 1Homo sapiens (human)
Bcl-2 family protein complexBcl-2-like protein 1Homo sapiens (human)
mitochondrial outer membraneBcl-2-like protein 1Homo sapiens (human)
mitochondrial inner membraneL-lactate dehydrogenase B chainBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID1184336Inhibition of lactate production in human HCC1954 cells after 6 hrs by spectrophotometry2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.
AID747631Inhibition of human recombinant carboxy-terminal his-tagged LDHA (1 to 331) expressed in Escherichia coli using pyruvate as substrate after 10 mins by UV endpoint analysis2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase.
AID724997Inhibition of human LDH-A2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors.
AID1184311Inhibition of human recombinant carboxy-terminal His-tagged LDHA by UV endpoint assay2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.
AID586286Inhibition of human LDH-A using pyruvate as substrate and NADH as cofactor at 125 uM after 5 mins by calorimetric assay relative to control2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells.
AID196930In vivo inhibition of succinate formation in the synaptosomal Gamma-amino-N-butyrate transaminase assay at 100 uM1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Aminomethyl-1,2,4-benzothiadiazines as potential analogues of gamma-aminobutyric acid. Unexpected discovery of a taurine antagonist.
AID296880Inhibition of pig heart mitochondrial MDH2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors.
AID681140TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000The Journal of physiology, Dec-01, Volume: 529 Pt 2Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle.
AID747621Inhibition of LDH in human HCC1954 cells assessed as lactate accumulation after 6 hrs2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase.
AID747627Inhibition of human recombinant carboxy-terminal his-tagged LDHB (1 to 333) expressed in insect cells using pyruvate as substrate after 10 mins by UV endpoint analysis2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase.
AID1276044Competitive inhibition of human LDH1 in presence of NADH2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Recent Update on Human Lactate Dehydrogenase Enzyme 5 (hLDH5) Inhibitors: A Promising Approach for Cancer Chemotherapy.
AID296879Inhibition of Plasmodium falciparum MDH2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors.
AID1184315Inhibition of human recombinant carboxy-terminal His-tagged LDHB by UV endpoint assay2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.
AID1411565Inhibition of human LDHB2017MedChemComm, Aug-01, Volume: 8, Issue:8
Discovery of human lactate dehydrogenase A (LDHA) inhibitors as anticancer agents to inhibit the proliferation of MG-63 osteosarcoma cells.
AID296881Inhibition of pig cytosolic MDH2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors.
AID724992Inhibition of LDH-A in human Ramos cells assessed as cellular lactate level at 10 mM after 4 hrs2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors.
AID296877Inhibition of Plasmodium falciparum LDH2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors.
AID1267459Inhibition of human LDHA using pyruvate as substrate assessed as disappearance of NADH2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Identification of a potent inhibitor targeting human lactate dehydrogenase A and its metabolic modulation for cancer cell line.
AID296878Inhibition of bovine heart LDH2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors.
AID1276043Competitive inhibition of human LDH5 in presence of NADH2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Recent Update on Human Lactate Dehydrogenase Enzyme 5 (hLDH5) Inhibitors: A Promising Approach for Cancer Chemotherapy.
AID1411564Inhibition of bovine heart LDHA2017MedChemComm, Aug-01, Volume: 8, Issue:8
Discovery of human lactate dehydrogenase A (LDHA) inhibitors as anticancer agents to inhibit the proliferation of MG-63 osteosarcoma cells.
AID724993Inhibition of LDH-A in human Ramos cells assessed as cellular lactate level at 10 mM after 1 hr2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors.
AID1798305Lactate Dehydrogenase Inhibition Assay from Article 10.1021/jm070336k: \\Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors.\\2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors.
AID1799904Enzyme Assay from Article 10.1021/cc060110n: \\Generation of oxamic acid libraries: antimalarials and inhibitors of Plasmodium falciparum lactate dehydrogenase.\\
AID1803001LDH Activity Assay from Article 10.3109/14756366.2011.566221: \\Oxamic acid analogues as LDH-C4-specific competitive inhibitors.\\2011Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 26, Issue:4
Oxamic acid analogues as LDH-C4-specific competitive inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (461)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990160 (34.71)18.7374
1990's70 (15.18)18.2507
2000's97 (21.04)29.6817
2010's121 (26.25)24.3611
2020's13 (2.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.25 (24.57)
Research Supply Index6.27 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index47.16 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials35 (7.09%)5.53%
Reviews16 (3.24%)6.00%
Case Studies3 (0.61%)4.05%
Observational0 (0.00%)0.25%
Other440 (89.07%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]